To investigate how various levels of exposure affect the metabolic activation pathways of benzene in humans and to examine the relationship between urinary metabolites and other biological markers, we have developed a sensitive and specific liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of urinary S-phenylmercapturic acid (S-PMA) and trans,transmuconic acid (t,t-MA). The assay involves spiking urine samples with [ 13 C 6 ]S-PMA and [ 13 C 6 ]t,t-MA as internal standards and clean up of samples by solid-phase extraction with subsequent analysis by liquid chromatography coupled with electrospray-tandem mass spectrometry-selected reaction monitoring (LC-ES-MS/MS-SRM) in the negative ionization mode. The efficacy of this assay was evaluated in human urine specimens from smokers and non-smokers as the benzene-exposed and non-exposed groups. The coefficient of variation of runs on different days (n ⍧ 8) for S-PMA was 7% for the sample containing 9.4 µg S-PMA/ l urine, that for t,t-MA was 10% for samples containing 0.07 mg t,t-MA/l urine. The mean levels of urinary S-PMA and t,t-MA in smokers were 1.9-fold (P ⍧ 0.02) and 2.1-fold (P ⍧ 0.03) higher than those in non-smokers. The mean urinary concentration (⍨SE) was 9.1 ⍨ 1.7 µg S-PMA/g creatinine [median 5.8 µg/g, ranging from not detectable (1 out of 28) to 33.4 µg/g] among smokers. In non-smokers' urine the mean concentration was 4.8 ⍨ 1.1 µg S-PMA/g creatinine (median 3.6 µg/g, ranging from 1.0 to 19.6 µg/g). For t,t-MA in smokers' urine the mean (⍨SE) was 0.15 ⍨ 0.03 mg/g creatinine (median 0.11 mg/ g, ranging from 0.005 to 0.34 mg/g); the corresponding mean value for t,t-MA concentration in non-smokers' urine was 0.07 ⍨ 0.02 mg/g creatinine [median 0.03 mg/g, ranging from undetectable (1 out of 18) to 0.48 mg/g]. There was a correlation between S-PMA and t,t-MA after logarithmic transformation (r ⍧ 0.41, P ⍧ 0.005, n ⍧ 46).
Introduction
Benzene is a ubiquitous environmental pollutant as well as an important industrial chemical. It is used in the manufacturing of a wide variety of consumer products and it is a constituent of tobacco smoke and of gasoline (1, 2) . A 30 cigarette/day smoker's personal daily uptake of benzene from mainstream cigarette smoke is~1500-1800 µg; exposure due to passive smoking can reach 50 µg/day. The intake of benzene from ambient air in the USA is~430-1530 µg/day (1, 3) . Occupational exposure to benzene in the USA is Ͻ16 mg/m 3 (3) . In developing countries, occupational benzene exposure can be one or two orders of magnitude higher than that in the USA (3) (4) (5) . Chronic exposure to high levels of benzene is associated with aplastic anemia, leukemia, especially acute myeloid leukemia, lung cancer, and possibly lymphoma and Hodgkin's lymphoma, as well as multiple myeloma (4) (5) (6) (7) . Studies of health effects of low levels of benzene exposure in humans are inconclusive (8) .
The molecular mechanisms responsible for the toxicity and carcinogenicity of benzene have not yet been fully elucidated. Several studies have indicated that metabolism of benzene to active intermediates is a prerequisite for its toxic and carcinogenic effects (9) . The metabolism of benzene is complex. The major metabolic routes consist of cytochrome P4502E1-mediated oxidation of benzene to an epoxide-oxepin intermediate and/or interaction of benzene with a hydroxyl ( • OH) radical to yield a hydroxy-cyclohexadienyl radical intermediate. These intermediates can lead to the formation of ring-hydroxylated metabolites such as phenol, hydroquinone, catechol and 1,2,4-benzenetriol; open-ring products, such as trans,trans-muconaldehyde and trans,trans-muconic acid (t,t-MA); and also dimeric products, such as biphenyl and hydroxylated biphenyls ( Figure 1 ) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The phenolic metabolites can undergo further oxidation to the corresponding reactive semiquinones and quinones and then react with cellular macromolecules, or form glucuronide and sulfate conjugates which are excreted in urine (21) (22) (23) . Benzene oxide can also react with glutathione, which is excreted in urine as S-phenylmercapturic acid (S-PMA) ( Figure 1 ).
It is not clearly known how the exposure to benzene at various dose levels affects the metabolic activation pathways in humans. We aim to develop sensitive and specific liquid chromatography-electrospray-tandem mass spectrometry (LC-ES-MS/MS) assays for quantitation of the metabolites to investigate the role of dose level on the metabolism of benzene in humans and to study the relationship of these metabolites to other biological markers (24) .
During the past decade, several HPLC and gas chromatography-mass spectrometry (GC-MS) methods have been employed for the measurement of urinary t,t-MA and S-PMA . Generally, HPLC-UV chromatograms of urinary extracts, especially from smokers, contain several compounds that elute in the vicinity of analytes that can interfere with the exact measurement of these analytes. The GC-MS method eliminates such problems and allows the quantification of low levels of S-PMA and t,t-MA. However, the need for derivatization of each analyte to obtain more volatile compounds makes the GC-MS method less attractive for large transitional epidemiology studies. LC-ES-MS/MS has, over the past decade, gained widespread use for quantitation of drugs and their metabolites in biological matrices (46) . In the present study we have developed an LC-ES-MS/MS assay for simultaneous quantification of two minor urinary benzene metabolites, namely urinary S-PMA and t,t-MA. The feasibility and efficacy of this assay have been examined in a pilot study for cigarette smokers as subjects with low benzene exposure and with non-smokers as a control group. ]aniline ( 13 C 6 , 99%) were purchased from Cambridge Isotope Laboratory (Andover, MA). Sodium nitrite, N-acetyl-L-cysteine and copper were bought from Aldrich (Milwaukee, WI) and Whatman's strong anionic exchange (SAX) cartridges (1000 mg) were from Fisher Scientific (Fair Lawn, NJ). Mono-and di-sodium phosphates were purchased from Sigma (St Louis, MO). Unless specified, solvents used were of HPLC grade from J.T.Baker (Phillipsburg, NJ).
Materials and methods

Chemicals
Animals
The Charles River Breeding Laboratories (North Wilmington, MA) supplied male F344/N rats. The rats were 12 weeks old at the onset of experiments. Synthesis of [ 13 C 6 ]S-PMA internal standard and unlabeled S-PMA [ 13 C 6 ]S-PMA was prepared from [ 13 C 6 ] aniline by the Gattermann reaction as shown in Figure 2 (47). In brief, [ 13 C 6 ]aniline (0.5 g; 5.3 mmol) was added to concentrated HCl (0.7 ml), diluted with H 2 O (1.5 ml) and HCl (1 ml) and a solution of NaNO 2 (1.4 ml; 6 mmol) was added to the resulting suspension while the temperature was kept below 5°C. While stirring, the formed phenyldiazonium salt mixture was added to an N-acetyl-L-cysteine solution (7.5 ml; 4.8 mmol) and the resulting orange precipitate was centrifuged. The wet solid of N-acetyl-S-phenyldiazol-L-cysteine was dissolved in EtOH (6 ml) and after adding freshly prepared copper (0.64 g) and H 2 O (14 ml), the suspension was refluxed at 80°C for 1.5 h. C]benzene (1 mCi/mmol)/kg body wt in 0.2 ml corn oil once a day for 3 days. The urine voids were collected at 0°C during exposure and after exposure on day 4; they were then stored at -20°C until analysis. [ 14 C]-and [ 13 C 6 ]-labeled standards were isolated from the urine by the method described previously (25) . In brief, urine samples were first subjected to solid-phase extraction clean up procedures, followed by HPLC purification.
Optimal condition for clean up of urine samples by solid-phase extraction before LC-ES-MS/MS analysis
The optimal condition for purification of urine samples by solid phase extraction was determined by spiking pooled smokers' urine with either 
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Fig. 3. Outline of biological sample preparation prior to LC-ES-MS/MS analysis for S-PMA and t,t-MA.
of the sorbed material from the SAX cartridge with different combinations and volumes of eluates. One milliliter fractions of each eluate were collected and radioactivity measured. Fractions containing radioactive materials were pooled and analyzed by HPLC as described below. The optimal condition for maximal recovery of both analytes from the SAX cartridge, shown in Figure  3 , was used for clean up of human urine samples as described below.
Clean-up of human urine samples
One-milliliter urine samples, spiked with 15 ng of [ 13 C 6 ]S-PMA and 30 ng of [ 13 C 6 ]t,t-MA as internal standards, were passed through an SAX cartridge that was preconditioned with 5 ml of MeOH and 5 ml of H 2 O. The cartridge was eluted with 3 ml of H 2 O (fraction 1), then with 3 ml of 5 mM phosphate buffer, pH 7 (fraction 2), 3 ml of 1% aqueous acetic acid (fraction 3) and, finally, the analytes of interest were eluted with 4 ml of 10% aqueous acetic acid (fraction 4). Analytes eluted as fraction 4 were extracted with 3ϫ5 ml of EtOAc; these extracts were combined and evaporated to dryness under N 2 at room temperature. The residue was dissolved in 150 µl of MeOH:1% aqueous acetic acid (20:80 v/v) and a 30-µl sample of this solution was analyzed by LC-ES-MS/MS-SRM (Figure 3) .
LC-ES-MS/MS analysis of S-PMA and t,t-MA
The HPLC features included a Waters Model 600 pump, a Rheodyne model 7120 injector and a Phenomenex Ultramex 5-µ C-18 narrow-bore column (250ϫ2.0 mm). A pre-injector splitter was utilized to reduce the flow-rate from 0.9 ml/min (HPLC pump) to 160 µl/min. A linear gradient from 80% solvent A (0.5% aqueous acetic acid), 20% solvent B (MeOH) to 100% solvent B over 5 min was employed in the elution program for analysis of S-PMA and t,t-MA.
The HPLC was interfaced with a Finnigan TSQ 700 triple-stage quadrupole mass spectrometer (San Jose, CA) via an electrospray source. The mass spectrometer was operated in the negative ion mode. The spray voltage was 4.1 kV, the capillary temperature 220°C. The liquid flow was introduced into the mass spectrometer at a rate of 160 µl/min without post-column splitting. For SRM, the first quadrupole (Q1) was used to select the precursor ion for the reaction and pass it on to Q2 where fragment ions were produced via collision with argon. The product ion of the reaction was monitored by Q3. The argon gas pressure in the collision cell (Q2) was adjusted so that the precursor beam suppression was~75%. A DEC Station no. 5000-120 computer was used to control the instrumentation, data acquisition and data processing. Standard calibration curves Stock standard solutions of S-PMA were prepared by dissolving 1 mg of the compound in 10 ml MeOH. t,t-MA solutions were prepared by dissolving 1 mg of t,t-MA in 10 ml of a mixture of 10:90 MeOH:0.5% aqueous acetic acid. The solutions were diluted with MeOH and spiked with internal standards 721 15 µg/l [ 13 C 6 ]S-PMA and 30 µg/l [ 13 C 6 ]t,t-MA to give a series of working standard solutions in a range generally present in biological samples. All standards were prepared on the day of analysis and the purity of each standard sample was checked by HPLC. Standard calibration graphs were constructed by plotting peak area ratios of analytes to those of the internal standards, measured at each nominal concentration. Reproducibility of the assay Inter-assay precision was determined by replicate analysis of pooled smokers' urine spiked with internal standards on different days. In addition, along with each run, a blank sample containing 1 ml H 2 O and the internal standard was also subjected to solid-phase extraction and LC-ES-MS/MS analysis. (25, 26) .
Human specimens
The Metropolitan Life Insurance Company's Testing Laboratories (Elmsford, NY) kindly provided urine specimens from men and women smokers and non-smokers. These specimens were collected on the spot from clients and each contained one tablet of a preservative that is generally used in clinical laboratories. Each tablet contained 84 mg potassium phosphate, 42 mg sodium benzoate, 54 mg benzoic acid, 8 mg sodium bicarbonate, 0.66 mg mercuric oxide, 1.5 mg polyvinylpyrrolidone (PVP), 1.7 mg magnesium stearate. All samples were frozen immediately and stored at -20°C until analysis. Creatinine and cotinine determination Urinary creatinine was determined with a Kodak Ektachem 500 ComputerDirected Analyzer and urinary cotinine was quantified by radioimmunoassay at the American Health Foundation's Clinical Biochemistry Facility by the previously described methods
Statistical analysis
The interrelationship between S-PMA and t,t-MA was assessed using linear regression, version 6.12 of the Statistical Analysis System (SAS), including 95% group and individual confidence limits. Since the two measures were found to be highly skewed and non-normally distributed, the logarithmic (base 10) transformation was used on the data points. For variables found below the detection limit, zero was imputed as a data point. All other statistical analyses (determination of mean, median, standard errors and linear regression for calibration graphs) were performed on a PC using Excel software; all reported P-values are two-tailed.
Results
Determination of urinary S-PMA and t,t-MA by LC-ES-MS/ MS-SRM in the negative ionization mode
The HPLC system provided separation of analytes; t,t-MA eluted at 9.35 m and S-PMA at 12 min (data not shown). The HPLC gradient is such that when the analytes were eluted from the column and introduced into the mass spectrometer, they were predominantly in MeOH.
The full scan mass spectrum of S-PMA showed an (M-1) -ion at m/z ϭ 238 [100, relative intensity] and a major product ion that resulted from loss of CO 2 and CH 2 ϭCH-NHCOCH 3 to yield an ion at m/z ϭ 109 [41] . The internal standard Figure 6 shows the calibration curves for S-PMA and t,t-MA. All points are the mean of three measurements. The calibration curves were linear at concentrations of 0.033-333 ng/injection for S-PMA (correlation coefficient, r Ͼ 0.99); and 1.6-3300 ng/injection for t,t-MA (r Ͼ 0.99).
Calibration curves, reproducibility assay and detection limits
Pooled urine samples from smokers were used to determine the reproducibility of the assays between runs on different days. The coefficient of variation between different runs (n ϭ 8) for S-PMA was 7% for the sample containing 9.4 µg S-PMA/l urine and 10% for the sample containing 0.07 mg t,t-MA/l urine.
The detection limit for S-PMA standard samples was 0.02 ng/injection and that for t,t-MA was 0.2 ng/injection, and the ratio of signal to noise was Ͼ5:1. For S-PMA, the lowest value quantified so far was 0.4 µg/l urine (corresponding to 0.08 ng/injection), the highest was 1950 µg/l (390 ng/injection; unpublished data from our current study for validation of the assay). For t,t-MA, the lowest concentration measured in this study was 0.003 mg/l urine (corresponding to 0.6 ng/injection). Blank samples subjected to the entire analytical procedure showed no detectable levels of either analyte. The analytical recoveries of spiked [ 14 C]S-PMA (120 µg/l urine) and [ 14 C]t,t-MA (0.1 mg/l urine), from the anion exchange cartridge, as determined by HPLC, were~75 and 85% (n ϭ 2), respectively. The total recovery of spiked [ 13 C 6 ]S-PMA (15 µg/l urine) in samples analyzed by LC-MS/MS was 43%, n ϭ 28 (ranging from 27 to 55%); the recovery of spiked [ 13 C 6 ]t,t-MA (0.03 mg/l urine) was 65%, n ϭ 28 (ranging from 40 to 107%). Figure 7 shows the concentrations of urinary S-PMA and t,t-MA in smokers and non-smokers. As shown in Table I , the mean Ϯ SE concentration of S-PMA in smokers was 9.1 Ϯ 1.7 µg/g creatinine and the median was 5.8 µg/g [ranging from non-detectable (1 out of 28) to 33.4 µg S-PMA/g]; the level of t,t-MA was 0.15 Ϯ 0.03 mg/g creatinine and the median was 0.11 mg/g (ranging from 0.005 to 0.34 mg/g). In non-smokers, the mean was 4.8 Ϯ 1.1 µg S-PMA/g creatinine, the median was 3.6 µg/g (ranging from 1.0 to 19.6 µg/g); the mean of t,t-MA was 0.07 Ϯ 0.02 mg/g creatinine, the median was 0.03 mg/g [ranging from non-detectable (1 out of 18) to 0.48 mg/g]. The levels of urinary S-PMA and t,t-MA in smokers were significantly higher than those in non-smokers, at P ϭ 0.02 and 0.03, respectively. The mean Ϯ SE concentration of urinary cotinine in smokers was 5.4 Ϯ 0.5 mg/g creatinine and the median was 3.4 mg/g (ranging from 0.56 to 15.5 mg/g). In non-smokers, corresponding data were 0.02 Ϯ 0.009 µg cotinine/mg creatinine, the median was 0.009 (ranging from non-detectable to 0.14 µg/g creatinine). Figure 8 illustrates the plot of S-PMA concentrations against urinary t,t-MA in the same sample after logarithmic transformation from both smokers and non-smokers (r ϭ 0.41, P ϭ 0.005, n ϭ 46). 
Quantitation of urinary S-PMA and t,t-MA in cigarette smokers and non-smokers
Discussion
A sensitive and specific LC-ES-MS/MS assay has been developed for the simultaneous measurement of two urinary benzene metabolites, S-PMA and t,t-MA, that are intended to be biomarkers of low levels benzene exposure in humans. The feasibility and efficacy of this assay have been examined in a pilot study for cigarette smokers as subjects with low benzene exposure and with non-smokers as the control group.
The optimal HPLC condition for S-PMA and t,t-MA was assessed with an elution gradient from an acidic pH to an organic solvent; thus the complete elution of t,t-MA from the HPLC column is achieved by acidic solvent elution and, when t,t-MA is introduced into the mass spectrometer, it is predominantly in MeOH. The optimal LC-ES-MS/MS conditions for the S-PMA and t,t-MA assay were obtained in the negative ionization mode. Operating in this mode, both S-PMA and t,t-MA and their corresponding internal standards generate prominently deprotonated molecular ions (M-1) -.
One problem encountered with the ES-MS method in quantitative analysis is the suppression of a monitored analyte ion by a co-eluting matrix component (48) . The solid-phase extraction applied prior to the LC-ES-MS/MS analysis eliminated the interfering matrix components to some extent. However, human urine samples, especially from smokers contain 723
Fig. 7. Levels of urinary S-PMA (A) and t,t-MA (B) in smokers and nonsmokers quantified by LC-ES-MS/MS-SRM method.
The mean levels of S-PMA and t,t-MA in smokers were 1.9-fold (P ϭ 0.02) and 2.1-fold (P ϭ 0.03) higher than those in non-smokers. many agents that cannot be removed completely from analytes. This could be the reason for the relatively low recoveries of [ 13 C]S-PMA. Stable isotope isomers of [ 13 C 6 ]S-PMA and [ 13 C 6 ]t,t-MA used as internal standards have nearly identical physicochemical properties and HPLC retention times similar to those of the urinary analytes. Thus, it is anticipated that any co-eluting unknown compound present in samples would have similar effects on both analytes and internal standards.
The efficacy of the newly developed LC-ES-MS/MS assay was evaluated by analyzing human urine specimens from 28 smokers and 18 non-smokers as benzene-exposed and nonexposed groups. The number of samples analyzed was based on the availability of specimens at this time. Urinary cotinine was used to assess the intensity of smoking. The mean concentration of cotinine in the urine of smokers was 5.4 mg/ g creatinine (~20-30 cigarettes/day), suggesting that the subjects in this study were heavy tobacco smokers. This pilot study indicated that the mean concentrations of S-PMA and t,t-MA in the urine of smokers were, respectively, 1.9-fold (P ϭ 0.02) and 2.1-fold (P ϭ 0.03) higher than those in urine of non-smokers ( Figure 7 ; Table I ).
The mean concentration of S-PMA in smokers quantified by LC-ES-MS/MS was 9.1 µg/g creatinine and that in nonsmokers was 4.8 µg/g creatinine. The concentrations of urinary S-PMA reported in the literature (analyzed by GC-MS and HPLC) are 3.61 and 9.4 µg S-PMA/g creatinine for smokers and 1.99 and 1.5 µg S-PMA/g creatinine for non-smokers (35, 38) . Similarly, the mean concentrations of t,t-MA in the current study were 0.15 mg/g in smokers and 0.07 mg/g creatinine in non-smokers. Levels of t,t-MA reported so far (mostly analyzed by HPLC) in smokers range from 0.14 to 0.61 mg/g creatinine and those in non-smokers range from 0.05 to 0.21 mg/g creatinine (25, 26, 33, 35, (37) (38) (39) (40) (41) (42) (43) (44) (45) . Thus, current values are in agreement with the literature data.
However, it appears that in most studies measurement of t,t-MA by HPLC resulted in higher values. This could partially be due to co-elution of unknown compounds with t,t-MA. An alternative source of urinary t,t-MA is sorbic acid (CH 3 CHϭCHCHϭCHCOOH). This preservative is used in certain foods, cosmetics and pharmaceutical products and its metabolism leads to t,t-MA (27, 43, 44) . For persons in the USA, the uptake of sorbic acid from food is estimated to be 6-30 mg/day and~0.12% of the sorbic acid dose is excreted in urine as t,t-MA. About 75% of t,t-MA is excreted within 6 h after ingestion of sorbic acid (43, 44) . Thus, collecting urine samples many hours after a meal can minimize interference of t,t-MA from ingested sorbic acid. It has been reported that dietary intake of sorbic acid accounts for 5-25% of the background t,t-MA excretion in smokers and for 10-50% in non-smokers (43, 44 S-PMA appears to be a better biomarker of benzene exposure than t,t-MA (unpublished data). To our knowledge, there is no dietary source that would lead to the formation of urinary S-PMA. A linear regression analysis of logarithmic transformation pointed to a correlation between S-PMA and t,t-MA, r ϭ 0.41, P ϭ 0.005 ( Figure 8 ). Urinary S-PMA in workers exposed to 0.5 p.p.m. benzene has been reported in the range from 7.2 to 25 µg/g creatinine. Similarly, the predicted excretion of t,t-MA ranged from 0.39 to 1.1 mg/g creatinine for 0.5 p.p.m. benzene exposure (34, 35, 38, 45) . Assuming that the uptake of benzene by smokers is 1.8 mg/day and the respiratory rate is 10 l air/min, the levels of S-PMA and t,t-MA excreted from uptake of benzene in cigarette smoke were estimated to be 1.63-5.9 µg/g creatinine and 0.09-0.26 mg/g creatinine, respectively. The enhanced levels of 4.3 µg S-PMA/g creatinine (from 4.8 to 9.1) and 0.08 mg t,t-MA/g creatinine (from 0.07 to 0.15) observed in smokers compared with non-smokers are in good agreement with the estimated ranges derived from occupational exposure to benzene.
There was inter-individual variation in the ratio of urinary excretion of t,t-MA to S-PMA from 1 to 146. This interindividual variation may be due to differences in the detoxification of benzene epoxide by glutathione, or these metabolites may be derived from different intermediates, or, alternatively, they may stem from varying amounts of ingested sorbic acid. The median ratio of t,t-MA/S-PMA in smokers was 10; the corresponding ratio among non-smokers was 6. These data suggest that smoking may alter the activation of benzene pathways and enhance the ratio of t,t-MA to S-PMA. In laboratory animal experiments and in a physiological model study, it has been shown that as the concentration of benzene exposure increases, its metabolism is shifted toward production of S-PMA (13, 17, 34) . On the other hand, the formation of t,t-MA has been shown to increase when mice were exposed to lower doses of benzene (18) . Thus, one would expect that in smokers, who are exposed to higher levels of benzene than non-smokers, the ratio of t,t-MA to S-PMA should be less than that in non-smokers. However, the current results are contradictory to that expectation. The enhancing effect of cigarette smoking on the t,t-MA to S-PMA ratio could be due to altered benzene metabolism in favor of the hydroxycyclohexadienyl intermediate; indeed tobacco smoke increases the formation of • OH (50) .
In conclusion, the HPLC separation coupled with an electrospray-interfaced MS/MS method to determine S-PMA and t,t-MA simultaneously is a practical, sensitive and specific assay, from a laboratory standpoint, and enables detection of the background levels of benzene exposure in the general population. These biomarkers of benzene are currently being validated in experiments with known benzene exposures.
